Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03257644 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT03257644 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 70 participants.
The verdict
NCT03257644, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics (PK) of topical ruxolitinib cream applied to pediatric subjects (age ≥ 2 to 17 years) with atopic dermatitis (AD).
Interventions
- DRUG Ruxolitinib phosphate cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2020-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03257644
The ClinicalTrials.gov registry entry for NCT03257644 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib phosphate cream is the first listed.
NCT03257644 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03257644 about?
NCT03257644 is a clinical study titled "A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis". The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics (PK) of topical ruxolitinib cream applied to pediatric subjects (age ≥ 2 to 17 years) with atopic dermatitis (AD).
What is the current status of trial NCT03257644?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2017-09-21. Estimated completion is 2020-10-07.
What interventions are being tested in trial NCT03257644?
The interventions under investigation include: Ruxolitinib phosphate cream (DRUG).
Who is sponsoring clinical trial NCT03257644?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.